CV-301 is under clinical development by Bavarian Nordic and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CV-301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CV-301 (PANVAC-VF) is under development for the treatment of solid tumors, metastatic colorectal cancer (adenocarcinoma). It is administered subcutaneously. The vaccine comprises of recombinant vaccinia virus (PANVAC-V, inalimarev) and recombinant fowlpox virus (PANVAC-F, falimarev) expressing transgenes for the tumor-associated antigens MUC-1 (mucin-1) and CEA (carcinoembryonic antigen) along with a triad of costimulatory molecules (TRICOM), which includes B7.1, ICAM-1, and LFA-3. It was also under development for lung, non-muscle invasive bladder cancer (NMIBC), ovarian cancer, metastatic breast cancer, adenocarcinoma of the pancreas, non-small cell lung cancer, metastatic adenocarcinoma of the pancreas and metastatic transitional (urothelial) tract cancer.
Bavarian Nordic overview
Bavarian Nordic is a vaccine company that develops, manufactures and commercializes vaccines for the prevention of life-threating diseases. The company develops its products using poxvirus-based technology platforms including modified vaccinia Ankara –Bavarian Nordic (MVA-BN). The company’s marketed products include JYNNEOS for smallpox and monkeypox; Encepur for tick-borne encephalitis; MVABEA for ebola; and Rabipur/RabAvert for rabbies. Its pipeline products are intended for the treatment of smallpox, COVID-19, respiratory syncytial virus, HER2- and brachyury-expressing cancers and Ebola infections. Bavarian Nordic has collaboration with the US government and various institutes, to develop its product candidates for the treatment of cancer and infectious diseases. It has a presence in the US, Denmark, Switzerland and Germany. Bavarian Nordic is headquartered in Hellerup, Denmark.
For a complete picture of CV-301’s drug-specific PTSR and LoA scores, buy the report here.